Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Inhibition of the interferon antiviral response by hepatitis C virus.

Hiscott J, Lin R.

Expert Rev Clin Immunol. 2006 Jan;2(1):49-58. doi: 10.1586/1744666X.2.1.49.

PMID:
20477087
2.

Management issues in chronic viral hepatitis: hepatitis C.

Sievert W.

J Gastroenterol Hepatol. 2002 Apr;17(4):415-22. Review.

PMID:
11982722
3.

Pathogenesis, diagnosis and management of hepatitis C.

Boyer N, Marcellin P.

J Hepatol. 2000;32(1 Suppl):98-112. Review.

PMID:
10728798
4.

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Seeff LB, Hoofnagle JH.

Clin Liver Dis. 2003 Feb;7(1):261-87. Review.

PMID:
12691470
5.

Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease.

Hiscott J, Lacoste J, Lin R.

Biochem Pharmacol. 2006 Nov 30;72(11):1477-84. Epub 2006 Jul 31.

PMID:
16876765
6.

HCV-hepatocellular carcinoma: new findings and hope for effective treatment.

Dash S, Haque S, Joshi V, Prabhu R, Hazari S, Fermin C, Garry R.

Microsc Res Tech. 2005 Nov;68(3-4):130-48. Review.

PMID:
16276514
7.

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.

Brown NA.

Expert Opin Investig Drugs. 2009 Jun;18(6):709-25. doi: 10.1517/13543780902854194 . Review.

PMID:
19426125
8.

Epidemiology and clinical aspects on hepatitis C.

Higuchi M, Tanaka E, Kiyosawa K.

Jpn J Infect Dis. 2002 Jun;55(3):69-77. Review.

PMID:
12195046
9.

[Immunology of hepatitis C: clinical significance of T cell response].

Shin EC.

Korean J Hepatol. 2006 Jun;12(2):140-53. Review. Korean.

10.

Treating hepatitis C infection in liver transplant recipients.

Terrault NA, Berenguer M.

Liver Transpl. 2006 Aug;12(8):1192-204. Review.

11.

Hepatitis C virus and liver transplantation.

Ahmed A, Keeffe EB.

Clin Liver Dis. 2001 Nov;5(4):1073-90. Review.

PMID:
11685796
12.

Ribavirin in the treatment of hepatitis C.

Abonyi ME, Lakatos PL.

Anticancer Res. 2005 Mar-Apr;25(2B):1315-20.

13.

Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.

Njoroge FG, Chen KX, Shih NY, Piwinski JJ.

Acc Chem Res. 2008 Jan;41(1):50-9. doi: 10.1021/ar700109k. Review.

PMID:
18193821
14.

Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses.

Tanikawa K.

Curr Pharm Des. 2006;12(11):1371-7. Review.

PMID:
16611121
15.
16.

Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.

Calleja JL, Albillos A, Moreno-Otero R, Rossi I, Cacho G, Domper F, Yebra M, Escartín P.

Aliment Pharmacol Ther. 1999 Sep;13(9):1179-86.

17.

Recent development of therapeutics for chronic HCV infection.

Huang Z, Murray MG, Secrist JA 3rd.

Antiviral Res. 2006 Sep;71(2-3):351-62. Epub 2006 Jun 23. Review.

PMID:
16828888
18.

Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.

Beaulieu PL.

Expert Opin Ther Pat. 2009 Feb;19(2):145-64. doi: 10.1517/13543770802672598. Review.

PMID:
19441916
19.

Chronic hepatitis C.

Sharara AI.

South Med J. 1997 Sep;90(9):872-7. Review.

PMID:
9305294
20.

[Pathogenesis of hepatitis C virus infection].

Montaño-Loza A, Meza-Junco J, Remes-Troche JM.

Rev Invest Clin. 2001 Nov-Dec;53(6):561-8. Review. Spanish.

PMID:
11921530

Supplemental Content

Support Center